Previous maternal studies

Immunising Mums Against Pertussis (iMAP2)

This study will be assessing two whooping cough vaccines used in pregnancy. Vaccinating mothers during pregnancy allows their baby to be protected in the first weeks of their life, when they are at greatest risk, as the antibodies from the mum cross the placenta to the baby. Both whooping cough vaccines also give protection against tetanus, diphtheria and polio. This study will assess the antibodies in both mother and baby, reassuring them that they have protection. It will also help to ensure the best protection is offered to our population.

iMAP2 –

Group B Streptococcus

Streptococcus agalactiae (group B streptococcus, GBS) is an important cause of serious infections in infants and pregnant women (e.g. septicaemia, pneumonia, meningitis). Early onset GBS disease may be prevented by antibiotics given intravenously to the mother during labour. Late onset disease however is not currently preventable. A vaccine against GBS has been developed and is currently being tested in pregnant women.  We therefore need to collect the best available evidence in order to assess the impact of current prevention guidelines as well as providing the baseline for a GBS vaccine program.


The main aim of this study is to determine if giving the RSV F vaccine (against Respiratory Syncytial Virus) during the last third of pregnancy can prevent severe lung disease caused by RSV in infants. Children with an RSV illness are most likely to have cold-like symptoms like cough, stuffy or runny nose, and breathing problems. These can be more severe in infants that are born too early or that have heart and lung problems and can be life-threatening and in rare cases can cause death. In addition, due to changes in the immune system during pregnancy, pregnant women may themselves be more susceptible to viral infections and so RSV may be more serious in pregnancy. Vaccines against RSV disease are being developed. However, vaccination in very young infants is not very effective. A different strategy that may help to prevent RSV disease in the young infant is to vaccinate women during pregnancy with an RSV vaccine. This strategy aims to provide direct protection to the new-born against this disease as the antibodies made by the mother are passed to the baby through the placenta and umbilical cord. This study will check if the vaccine protects your baby (or even you) from RSV infection for 3- 6 months. Studies have shown that babies that get high levels of RSV antibodies from their mother are less likely to be admitted to hospital for RSV disease during the first 3 months of life.


Cytomegalovirus (CMV) is a common virus which in healthy adults causes only a mild illness. If a woman catches CMV for the first time when she is pregnant however, there is a chance that the infection can be passed on to her baby. In a small number of cases, this can cause problems in the baby, such as deafness or delayed development. CMV is the most common infection passed from mother to baby and there is currently no vaccine available to protect women and their infants. Some studies have shown that small changes to day to day activities during pregnancy can help reduce the risk of catching CMV and we have developed an educational film to explain these. We will investigate whether watching this film can reduce the risk of acquiring CMV for the first time.